Introduction {#sec1}
============

The dopamine-3 (D~3~) receptor subtype has been identified as an important target for agents currently in clinical use for the treatment of a variety of neurological diseases, including schizophrenia, Parkinson's disease, and depression. However, all of the clinically approved drugs targeting the D~3~ receptor have a very limited selectivity over D~2~ receptors and other off-targets.^[@ref1],[@ref2]^ Considerable effort has been devoted in the past decade to the design of potent and selective D~3~ ligands.^[@ref1]−[@ref16]^ Although it was initially challenging to design highly selective D~3~ ligands, due to the high degree of sequence homology between the D~2~ and D~3~ receptors, recent SAR studies have demonstrated the feasibility of such a design. For example, upon the basis of pramipexole (**1**), a potent D~3~ agonist with only modest selectivity over the D~2~ receptor, we designed and prepared compounds CJ-1638 (**2**) and CJ-1639 (**3**), which are potent and selective D~3~ agonists (Figure [1](#fig1){ref-type="fig"}).^[@ref14]^ Compounds **2** and **3** bind to the D~3~ receptor, with *K*~i~ values \<1 nM and display \>1000-fold selectivity over both the D~1~ and D~2~ receptors. Further, with the determination of the D~3~ receptor crystal structure and derived computational models, the small molecule SARs have been fortified.^[@ref17]^ Not only have highly D~3~ receptor selective ligands been discovered, but the roles of the orthosteric site and a secondary binding pocket have further defined the drug--protein interactions responsible for affinity, selectivity, and efficacy.^[@ref18],[@ref19]^

![Chemical structures of pramipexole and two previously reported selective D~3~ agonists.](jm-2013-01798r_0001){#fig1}

Potent and selective D~3~ antagonists may have a therapeutic potential for the treatment of drug addictions and relate disorders.^[@ref2]^ Herein we report the design and SAR study of a new class of D~3~ antagonists. Analysis of several classes of known D~3~ antagonists shows that their structures can be divided into three regions as shown in Figure [2](#fig2){ref-type="fig"}: the headgroup (in blue), the linker (in black), and the tail (in red). The headgroup consists of a basic amine tethered to an aromatic group (typically phenyl), substituted with a hydrogen bonding acceptor (a nitrile in **4**([@ref3]) or a methoxyl group in **6**([@ref20])), or one or two small hydrophobic groups in **5**([@ref21],[@ref22]) and **7**.^[@ref13]^ We first selected a new "head" group with these features for the design and development of a new class of D~3~ antagonists.

![Chemical structures of previous dopamine D~3~ receptor antagonists.](jm-2013-01798r_0002){#fig2}

Among potential "head" groups under consideration, we found that tranylcypromine (**8**, Figure [3](#fig3){ref-type="fig"}) was attractive because, like pramipexole (**1**) and **7**, it contains a structurally rigid phenethylamine moiety. Because the affinities of tranylcypromine for the dopamine receptors are not known, we first tested the commercially available, racemic tranylcypromine in our dopamine receptor binding assays using rat brain.^[@ref23],[@ref24]^ Our data showed that tranylcypromine has a weak affinity for the D~3~ receptor with a *K*~i~ value = 12.8 μM and displays 4-fold selectivity over the D~2~ receptor (Table [1](#tbl1){ref-type="other"}). Although tranylcypromine is a weak D~3~ ligand and has a very limited selectivity over the D~2~ receptor, it was used as a starting point for our SAR study, which has ultimately yielded a class of potent and selective D~3~ antagonists.

![Chemical structures and absolute configurations of the novel compounds.](jm-2013-01798r_0003){#fig3}

###### Binding Affinities at Rat Dopamine D~1~-Like, D~2~-Like, and D~3~ Receptors

                       *K* ± SEM (nM)    selectivity                               
  -------------------- ---------------- -------------- ---------------- ---------- ------
  **2**                0.40 ± 0.087        725 ± 45    1616 ± 167       1827       4074
  **6**                1.2 ± 0.10          468 ± 51    1042 ± 101       390        868
  **7**                46 ± 5.6          18417 ± 2251  38807 ± 3038     400        484
  (±)-**8**            12793 ± 1870      58737 ± 5908  116250 ± 15103   4.3        9.1
  (1*S*,2*R*)-**9**    1171 ± 91         95593 ± 5877  122700 ± 10120   82         105
  (1*R*,2*S*)-**9**    1195 ± 71         96648 ± 9225  90587 ± 3531     81         76
  (1*S*,2*R*)-**10**   108 ± 7.5          2137 ± 247   3088 ± 33        20         29
  (1*R*,2*S*)-**10**   44 ± 5.8           1312 ± 170   2825 ± 297       30         64
  (±)-**11**           4.6 ± 0.40          \>100000    2201 ± 150       \>21000    479
  (±)-**12**           19 ± 1.8            503 ± 63    743 ± 71         26         39
  (±)-**13**           28 ± 2.1            \>300000    1804 ± 126       \>29000    64
  (1*S*,2*R*)-**11**   457 ± 34            \>100000    20653 ± 2035     \>218      45
  1*R*,2*S*)-**11**    2.7 ± 0.30          \>300000    25810 ± 1867     \>100000   9559

Results and Discussion {#sec2}
======================

Our previous study showed that the propyl substituent on the amine group in pramipexole enhances the binding affinity to the D~3~ receptors by at least 1 order of magnitude.^[@ref14]^ We therefore investigated whether substitution of a propyl group on the primary amine in tranylcypromine would improve the binding affinity to the D~3~ receptor. Chiral resolution of racemic 2-phenyl-cyclopropanamine according to the reported method,^[@ref25]^ followed by addition of the propyl group afforded two stereoisomers (1*S*,2*R*)-**9** and (1*R*,2*S*)-**9**. Binding data showed that both (1*S*,2*R*)-**9** and (1*R*,2*S*)-**9** bind to the rat D~3~ receptor with *K*~i~ values of 1.2 μM and display approximately 80-fold selectivity over the D~2~ receptor (Table [1](#tbl1){ref-type="other"}). Thus, addition of a propyl group to the primary amine in tranylcypromine indeed improves the binding affinity for the D~3~ receptor, as well as the selectivity over the D~2~ receptor.

Our previous study showed that introduction of appropriate linker and tail groups in compounds **2** and **3** onto the amine group in pramipexole significantly enhanced its selectivity for the rat D~3~ receptor over that for the D~2~ receptor.^[@ref14]^ Accordingly, we synthesized (1*S*,2*R*)-**10** and (1*R*,2*S*)-**10** with the same linker and tail groups used in compound **2** appended onto the amine group in compounds (1*S*,2*R*)-**9** and (1*R*,2*S*)-**9**. Compounds (1*S*,2*R*)-**10** and (1*R*,2*S*)-**10** have *K*~i~ values of 108 and 44 nM to the rat D~3~ receptor, respectively, representing a 10--20-fold improvement over (1*S*,2*R*)-**9** and (1*R*,2*S*)-**9**. However, in contrast to the marked improved selectivity of compound **2** over pramipexole for the D~3~ receptor over the D~2~ receptor observed in our previous study,^[@ref14]^ both (1*S*,2*R*)-**10** and (1*R*,2*S*)-**10** only have modest 20--30-fold selectivity over the rat D~2~ receptor.

Addition of a hydrophobic group such as Cl to the phenyl ring has been shown to enhance the binding affinity of antagonists to the D~3~ receptor. We have therefore synthesized three compounds (**11**, **12**, and **13**) in which a Cl substitution was installed in the *para*-, *ortho*-, or *meta*-position of the phenyl ring of **10**. Because (1*S*,2*R*)-**10** and (1*R*,2*S*)-**10** do not differ markedly in their binding affinity to the rat D~3~ receptor or their selectivity over the rat D~2~ receptor, we first synthesized and evaluated the racemic forms of **11**--**13**. Compounds (±)-**11**, (±)-**12**, and (±)-**13** have *K*~i~ values of 4.6, 19, and 28 nM, respectively, to the rat D~3~ receptor. (±)-**11** and (±)-**13** also display high (\>10000 times) selectivity over the rat D~2~ receptor, neither compound showing measurable binding to the rat D~2~ receptor at 100 μM. However, both (±)-**11** and (±)-**13** have significant affinity for the rat D~1~-like receptors with *K*~i~ values of 2.2 and 1.8 μM, respectively.

Because (±)-**11** showed high affinity for the rat D~3~ receptor, we resolved the stereoisomers, (1*S*,2*R*)-**11** and (1*R*,2*S*)-**11**). (1*R*,2*S*)-**11** has a *K*~i~ value of 2.7 nM to the rat D~3~ receptor and is \>100 times more potent than (1*S*,2*R*)-**11** (*K*~i~ = 457 nM). Furthermore, (1*R*,2*S*)-**11** has no appreciable binding to the rat D~2~ receptor at concentrations as high as 300 μM and consequently has \>100,000-fold selectivity for the rat D~3~ receptor over the rat D~2~ receptor. (1*R*,2*S*)-**11** shows weak binding affinity to the D~1~-like receptors, with a *K*~i~ value of 25.8 μM, and has \>9000-fold selectivity for the rat D~3~ receptor over the rat D~1~-like receptors.

We next assessed the binding affinities of (±)-**11**, (±)-**12**, (±)-**13**, and (1*R*,2*S*)-**11** to the human D~2~ and D~3~ receptors using transfected cell lines and included several previously reported D~2~/D~3~ antagonists as controls. The data are provided in Table [2](#tbl2){ref-type="other"}.

###### Binding Affinities at Human D~2~ and D~3~ Receptors

                           *K*~i~ ± SEM (nM)   selectivity     
  ------------------------ ------------------- --------------- -----
  (±)-**11**               2.61 ± 0.19         667 ± 230       256
  **(±)-12**               22.1 ± 1.87         923 ± 213       42
  **(±)-13**               37.9 ± 3.57         1,220 ± 33.7    32
  (1**R**,2**S**)-**11**   2.80 ± 0.556        623 ± 105       223
  *N*-methylspiperone      0.265 ± 0.008       0.133 ± 0.009   0.5
  eticlopride              0.134 ± 0.004       0.086 ± 0.001   0.6
  raclopride               13.4 ± 0.695        12.7 ± 1.21     1
  butaclamol               6.39 ± 0.58         2.58 ± 0.473    0.4
  PG619                    6.70 ± 0.77         1,090 ± 21      163
  PG648                    1.88 ± 0.11         746 ± 123       397

Racemic compounds (±)-**11**, (±)-**12**, (±)-**13**, and the pure enantiomer (1**R**,2*S*)-**11** have *K*~i~ values to the human D~3~ receptor of 2.61, 22.1, 37.9, and 2.80 nM, respectively. These values are similar to their respective *K*~i~ values of 4.6, 19, 26, and 2.7 nM to the rat D~3~ receptor. Compounds (±)-**11**, (±)-**12**, (±)-**13**, and (1*R*,2*S*)-**11** have *K*~i~ values, respectively, of 667, 923, 1220, and 623 nM, to the human D~2~ receptor. Thus, with the exception of (±)-**12**, these compounds have higher binding affinities to the human D~2~ receptor than to the rat D~2~ receptor. The selectivities of (±)-**11** and (±)-**13** and the pure enantiomer (1*R*,2*S*)-**11** for the human D~3~ receptor over the human D~2~ receptor are 256-, 32-, and 223-fold, respectively. These are lower than the selectivities observed for these compounds for the rat D~3~ receptor over the rat D~2~ receptor. The known D~3~ antagonists *N*-methylspiperone,^[@ref26]^ eticlopride,^[@ref27]^ raclopride,^[@ref28]^ and butaclamol,^[@ref29]^ all bind to the human D~3~ receptor with high affinities but show no selectivity between the human D~2~ and D~3~ receptors (Table [2](#tbl2){ref-type="other"}). In comparison, PG619^[@ref22]^ and PG648,^[@ref12]^ two previously reported selective D~3~ antagonists, bind to the human D~3~ receptor with *K*~i~ values of 6.70 and 1.88 nM, respectively, displaying selectivities of 163- and 397-fold respectively, for the human D~3~ receptor over the human D~2~ receptor.

To assess the functional activity of (1*R*,2*S*)-**11** at the D~3~ receptor, we tested it in a DiscoveR~X~ D~3~ functional assay using the U2OS cell line transfected with human dopamine D~3~ receptor.^[@ref30]^ In this assay, a D~3~ agonist, such as pramipexole, stimulates β-arrestin binding to the D~3~ receptor, while a D~3~ antagonist, such as **6** (BP 897),^[@ref20]^ blocks the association of β-arrestin induced by a D~3~ agonist. Assessed in this manner, pramipexole has an agonist activity with an EC~50~ value of 3.7 ± 0.65 nM. (1*R*,2*S*)-**11** has no agonist activity (EC~50~ \> 100 μM), but it dose-dependently inhibits the binding of β-arrestin to the D~3~ receptor induced by 100 nM of pramipexole and has an IC~50~ value of 327 ± 126 nM (Table [3](#tbl3){ref-type="other"}). In comparison, **6** shows no agonist activity but has potent antagonist activity, with an IC~50~ value of 13 ± 1.7 nM (Table [3](#tbl3){ref-type="other"}). Hence, (1*R*,2*S*)-**11** is a potent D~3~ antagonist, albeit less potent than **6**. We performed a Schild regression analysis for (1*R*,2*S*)-**11** in the human D~3~ functional assay (Figure [4](#fig4){ref-type="fig"}). In these experiments, D~3~ activity, measured on the basis of β-arrestin binding to the receptor, was stimulated by pramipexole in the presence of three concentrations of (1*R*,2*S*)-**11**. The data were analyzed according to the methods of Kenakin.^[@ref31]^ In the Schild plot (the inset in Figure [4](#fig4){ref-type="fig"}), it can be seen that increasing concentrations of (1*R*,2*S*)-**11** shift the pramipexole dose--response curve to the right, consistent with antagonist activity, with a *K*~B~ value of 20 nM. The slope of the Schild plot was −0.83, close to unity, indicating that (1*R*,2*S*)-**11** is a competitive D~3~ antagonist.

###### Efficacy at the Human D~3~ Receptor in the DiscoveR~x~ PathHunter eXpress β-Arrestin Assay[a](#t3fn1){ref-type="table-fn"}

                        agonist activity  Antagonist Activity   
  -------------------- ------------------ --------------------- -----------
  **1**                    3.7 ± 0.65     100                       ND
  **6**                     \>100000                             13 ± 1.7
  (1*R*,2*S*)-**11**        \>100000                             327 ± 126

Data are the mean ± SEM of 3--6 independent determinations (2 determinations if inactive). ND = not determined.

![Schild analysis of (1*R*,2*S*)-**11** at the human D~3~ receptor in the DiscoveRx PathHunter eXpress β-arrestin assay. D~3~ activity was stimulated by pramipexole. Schild transformation (insert) indicated a pA2 of −7.96, corresponding to a KB value of 20 nM. The slope was −0.83. Data shown are representative of two independent determinations.](jm-2013-01798r_0004){#fig4}

The synthesis of compounds **9**--**13** is shown in Scheme [1](#sch1){ref-type="scheme"}. Enantiomerically pure (1*R*,2*S*)-2-phenylcyclopropanamine and (1*S*,2*R*)-2-phenylcyclo-propanamine were obtained by resolution of commercially available (±)-*trans*-2-phenylcyclopropylamine (**8**) according to the reported method.^[@ref25]^ Reductive amination of (1*R*,2*S*)-**8** and (1*S*,2*R*)-**8** using propionaldehyde and NaBH~4~ gave (1*R*,2*S*)-**9** and (1*S*,2*R*)-**9** in good yield. Reductive amination of (1*R*,2*S*)-**9** and (1*S*,2*R*)-**9** with *N*-(*cis*-3-hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide using sodium triacetoxyborohydride as a reductant gave (1*R*,2*S*)-**10** and (1*S*,2*R*)-**10**. Compounds (±)-**11**--(±)-**13** were prepared similarly. Reductive amination of the appropriate commercially available racemic chloro-substituted *trans*-2-phenylcyclopropanamine (±)-**14**--**16** afforded (±)-**17**--**19**. The final compounds (±)-**11**--**13** were prepared by reductive amination of (±)-**17**--**19** with *N*-(*cis*-3-hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide. *N*-(*cis*-3-Hydroxy-3-(2-oxo-ethyl)cyclobutyl)-2-naphthamide was prepared as described previously.^[@ref14]^

![Synthesis of **9**--**13**\
Reagents and conditions: (a) propionaldehyde, NaBH~4~, MeOH, RT; (b) *N*-(*cis*-3-hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide, NaBH(OAc)~3~, HOAc, DCM, RT, 4 h.](jm-2013-01798r_0005){#sch1}

The synthesis of (1*S*,2*R*)-**11** is shown in Scheme [2](#sch2){ref-type="scheme"}. The optically pure key intermediate (1*S*,2*S*)-2-(4-chlorophenyl)cyclopropane-carboxylic acid **24** was prepared according to a reported method.^[@ref32]^ Treatment of the acid chloride **20** with sodium (1*R*)-(+)-2,10-camphorsultam afforded the enoyl sultams **21** in excellent yield (\>93%). Reaction of **21** with diazomethane in the presence of a catalytic amount of palladium acetate gave a cyclopropanated diastereomeric mixture of (1*R*)-(+)-2,10-camphorsultam-(1*S*,2*S*)-2-phenylcyclopropane-carboxamide **22** and (1*R*)-(+)-2,10-camphorsultam-(1*R*,2*R*)-2-phenyl-cyclopropane-carboxamide **23** in a ratio of 7:1. Recrystallization from ethanol afforded pure cyclopropanoyl sultams **22**. Treatment of **22** with titanium isopropoxide in benzyl alcohol, followed by lithium hydroxide hydrolysis and acidification, afforded the cyclopropanecarboxylic acid (1*S*,2*S*)-**24**. Boc-protected (1*S*,2*R*)-2-phenylcyclopropylamine **25** was obtained from the carboxylic acid using a Curtius rearrangement of the corresponding acyl azide followed by addition of *t*-butanol to the isocyanate intermediate. Removal of the Boc group, followed by reductive amination, gave (1*S*,2*R*)-**17**. The final compound (1*S*,2*R*)-**11** was obtained by reductive-amination of (1*S*,2*R*)-**17** with *N*-(*cis*-3-hydroxy-3-(2-oxoethyl)cyclo-butyl)-2-naphthamide. (1*R*,2*S*)-**11** was made by a method similar to that used for (1*S*,2*R*)-**11**, except that (1*S*)-(−)-2,10-camphorsultam was used as a chiral auxiliary.

![Synthesis of (1*S*,2*R*)-**11**\
Reagents and conditions: (a) (1*R*)-(+)-2,10-camphorsultam, NaH, THF, 0 °C, 30 min, then RT overnight; (b) CH~2~N~2~, Pd(OAc)~2~, DCM, RT, 10 h; (c) (i)Ti(iOPr)~4~, BzOH, 150 °C, 30 min, (ii) 2 M LiOH, MeOH, RT, 2 h, (iii) 4 M HCI; (d) (i) ethyl chloroformate. Et~3~N, acetone, 0 °C, 2 h, (ii) NaN~3~,1 h, (iii) 90 °C, toluene, 3 h, (iv) ButOH, reflux, 16 h. (e) TFA, DCM, RT, 12 h; (f) propionaldehyde, NaBH~4~, MeOH, RT; (g) *N*-(*cis*-3-hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naprittiamlde, NaBH(OAc)~3~, HOAc, DCM, RT, 4 h.](jm-2013-01798r_0006){#sch2}

Summary {#sec3}
=======

Starting from tranylcypromine, we have designed and synthesized a class of potent and selective dopamine D~3~ receptor ligands. The best compound, (1*R*,2*S*)-**11**, had a *K*~i~ value of 2.7 nM to the rat D~3~ receptor and displayed a selectivity of \>100000-fold over the rat D~2~ receptor and \>9000-fold over the rat D~1~-like receptors. (1*R*,2*S*)-**11** binds to the human D~3~ receptor with a *K*~i~ value of 2.8 nM and displays 223-fold selectivity over the human D~2~ receptor. Functional data and Schild analysis showed that (1*R*,2*S*)-**11** is a potent and competitive antagonist at the human D~3~ receptor. (1*R*,2*S*)-**11** (CJ-1882) is being further evaluated for its pharmacokinetics, brain bioavailability, and therapeutic potential for the treatment of drug abuse.

Experimental Section {#sec4}
====================

General Methods {#sec4.1}
---------------

Solvents and reagents were obtained commercially and used without further purification. Reactions were monitored by TLC carried out on 250 μm silica gel plates 60F-254 (E. Merck) using UV light as visualizing agent. Silica gel 60, particle size 15--40 μm (E. Merck), was used for flash column chromatography. NMR spectra were recorded on a Bruker Avance 300 spectrometer (300 MHz). Chemical shifts (δ) are reported as δ values (ppm) downfield relative to TMS as an internal standard, with multiplicities reported in the standard manner. All final compounds have purities \>95%, as determined by HPLC (UV detection at 254 nm).

(1*S*,2*R*)-2-Phenyl-*N*-propylcyclopropanamine ((1*S*,2*R*)-**9**) {#sec4.2}
-------------------------------------------------------------------

Propionaldehyde (82 mg, 1.41 mmol) was added to a solution of (1*S*,2*R*)-2-phenylcyclopropanamine (188 mg, 1.41 mmol) in MeOH (10 mL), and the reaction mixture was stirred at room temperature for 2 h. Sodium borohydride (79 mg, 2.12 mmol) was then added, and the mixture was stirred at room temperature for 1 h. The reaction was quenched with H~2~O (30 mL) and extracted with ethyl acetate (40 mL). The residue was chromatographed (hexane:EtOAc = 50:50) to give (1*S*,2*R*)-**9** (178 mg, 72% yield) as a colorless oil. ^1^H NMR (CD~3~OD, 300 MHz) δ 7.37--7.12 (m, 5H), 3.20--3.08 (m, 2H), 2.97--2.90 (m, 1H), 2.56--2.45 (m, 1H), 1.82--1.70 (m, 2H), 1.57--1.45 (m, 1H), 1.36 (dd, *J* = 6.7, 14.4 Hz, 1H), 1.04 (t, *J* = 7.4 Hz). ^13^C NMR (CD~3~OD, 75 MHz) δ 139.42, 129.68, 127.91, 127.56, 50.88, 39.04, 22.32, 20.55, 13.35, 11.19.

(1*R*,2*S*)-2-Phenyl-*N*-propylcyclopropanamine ((1*R*,2*S*)-**9**) {#sec4.3}
-------------------------------------------------------------------

Propionaldehyde (82 mg, 1.41 mmol) was added to a solution of (1*R*,2*S*)-2-phenylcyclopropanamine (188 mg, 1.41 mmol) in MeOH (10 mL), and the reaction mixture was stirred at room temperature for 2 h. Sodium borohydride (79 mg, 2.12 mmol) was then added, and the mixture was stirred at room temperature for 1 h. The reaction was quenched with H~2~O (30 mL) and extracted with EtOAc (40 mL). The residue was chromatographed (hexane:EtOAc = 50:50) to give (1*R*,2*S*)-**9** (171 mg, 69% yield) as a colorless oil. ^1^H NMR (CD~3~OD, 300 MHz) δ 7.37--7.12 (m, 5H), 3.20--3.08 (m, 2H), 2.97--2.90 (m, 1H), 2.56--2.45 (m, 1H), 1.82--1.70 (m, 2H), 1.57--1.45 (m, 1H), 1.36 (dd, *J* = 6.7, 14.4 Hz, 1H), 1.04 (t, *J* = 7.4 Hz). ^13^C NMR (CD~3~OD, 75 MHz) δ 139.42, 129.68, 127.91, 127.56, 50.88, 39.04, 22.32, 20.55, 13.35, 11.19.

*N*-(*cis*-3-Hydroxy-3-(2-(((1*S*,2*R*)-2-phenylcyclopropyl)(propyl)-amino)ethyl)cyclobutyl)-2-naphthamide ((1*S*,2*R*)-**10**) {#sec4.4}
-------------------------------------------------------------------------------------------------------------------------------

*N*-(*cis*-3-Hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide (80 mg, 0.28 mmol), sodium triacetoxyborohydride (90 mg, 0.43 mmol), and AcOH (26 mg, 0.43 mmol) were added to a solution of (1*S*,2*R*)-**9** (50 mg, 0.28 mmol) in CH~2~Cl~2~ (20 mL). The mixture was stirred at room temperature for 4 h and then quenched by addition of H~2~O (30 mL). The mixture was extracted with CH~2~Cl~2~ (30 mL × 3). The organic solvent was removed under vacuum, and the residue was chromatographed (MeOH:EtOAc = 10:90) to give (1*S*,2*R*)-**10** (43 mg, 34% yield) as a colorless oil. ^1^H NMR (CD~3~OD, 300 MHz) δ 8.39 (s, 1H), 8.00--7.80 (m, 4H), 7.60--7.50 (m, 2H), 7.40--7.20 (m, 5H), 4.25--4.00 (m, 1H), 3.60--3.25 (m, 4H), 3.20--3.02 (m, 1H), 2.75--2.60 (m, 3H), 2.40--2.09 (m, 4H), 1.90--1.65 (m, 3H), 1.53 (dd, *J* = 7.1, 14.4 Hz, 1H), 1.05 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (CD~3~OD, 75 MHz) δ 169.90, 164.83, 138.89, 136.25, 133.99, 132.65, 129.99, 129.91, 129.31, 128.85, 128.76, 128.21, 127.86, 127.18, 124.91, 68.81, 58.31, 53.29, 46.48, 44.19, 44.09, 38.24, 23.66, 18.84, 14.49, 11.23.

*N*-(*cis*-3-Hydroxy-3-(2-(((1*R*,2*S*)-2-phenylcyclopropyl)(propyl)amino)-ethyl)cyclobutyl)-2-naphthamide ((1*R*,2*S*)-**10**) {#sec4.5}
-------------------------------------------------------------------------------------------------------------------------------

*N*-(*cis*-3-Hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide (80 mg, 0.28 mmol), sodium triacetoxyborohydride (90 mg, 0.43 mmol), and AcOH (26 mg, 0.43 mmol) were added to a solution of (1*R*,2*S*)-**9** (50 mg, 0.28 mmol) in CH~2~Cl~2~ (20 mL), and the mixture was stirred at room temperature for 4 h. The reaction was quenched by addition of H~2~O (30 mL), and the mixture was extracted with CH~2~Cl~2~ (30 mL × 3). The organic solvent was removed under vacuum, and the residue was chromatographed (MeOH:EtOAc = 10:90) to give (1*R*,2*S*)-**10** (36 mg, 29% yield) as a colorless oil. ^1^H NMR (CD~3~OD, 300 MHz) δ 8.39 (s, 1H), 8.00--7.80 (m, 4H), 7.60--7.50 (m, 2H), 7.40--7.20 (m, 5H), 4.25--4.00 (m, 1H), 3.60--3.25 (m, 4H), 3.20--3.02 (m, 1H), 2.75--2.60 (m, 3H), 2.40--2.09 (m, 4H), 1.90--1.65 (m, 3H), 1.53 (dd, *J* = 7.1, 14.4 Hz, 1H), 1.05 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (CD~3~OD, 75 MHz) δ 169.90, 164.83, 138.89, 136.25, 133.99, 132.65, 129.99, 129.91, 129.31, 128.85, 128.76, 128.21, 127.86, 127.18, 124.91, 68.81, 58.31, 53.29, 46.48, 44.19, 44.09, 38.24, 23.66, 18.84, 14.49, 11.23.

*N*-(*cis*-3-(2-((((±)-*trans*)-2-(2-Chlorophenyl)cyclopropyl)(propyl)-amino)ethyl)-3-hydroxycyclobutyl)-2-naphthamide ((±)-**12**) {#sec4.6}
-----------------------------------------------------------------------------------------------------------------------------------

*N*-(*cis*-3-Hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide (82 mg, 0.29 mmol), sodium triacetoxyborohydride (91 mg, 0.43 mmol), and AcOH (26 mg, 0.43 mmol) were added to a solution of (±)-**18** (60 mg, 0.29 mmol) in CH~2~Cl~2~ (20 mL), and the mixture was stirred at room temperature for 4 h. The reaction was quenched by addition of H~2~O (30 mL), and the mixture was extracted with CH~2~Cl~2~ (30 mL × 3). The organic solvent was removed under vacuum, and the residue was chromatographed (MeOH:EtOAc = 10:90) to give (±)-**12** (49 mg, 36% yield) as a colorless oil. ^1^H NMR (CD~3~OD, 300 MHz) δ 8.39 (s, 1H), 8.00--7.85 (m, 4H), 7.70--7.52 (m, 2H), 7.47 (dd, *J* = 1.6, 7.4 Hz, 1H), 7.40--7.20 (m, 2H), 7.09 (dd, *J* = 2.0, 7.4 Hz, 1H), 4.25--4.02 (m, 1H), 3.70--3.30 (m, 4H), 3.30--3.20 (m, 1H), 2.75--2.60 (m, 2H), 2.40--2.10 (m, 4H), 2.00--1.50 (m, 4H), 1.07 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (CD~3~OD, 75 MHz) δ 170.16, 136.48, 136.40, 135.76, 134.23, 132.87, 130.91, 130.19, 129.95, 129.52, 129.05, 128.97, 128.91, 128.06, 127.59, 125.09, 69.09, 58.35, 53.41, 46.50, 44.48, 44.29, 38.48, 34.56, 21.52, 18.85, 14.44, 11.42.

*N*-(*cis*-3-(2-((((±)-*trans*)-2-(4-Chlorophenyl)cyclopropyl)(propyl)-amino)ethyl)-3-hydroxycyclobutyl)-2-naphthamide ((±)-**11**) {#sec4.7}
-----------------------------------------------------------------------------------------------------------------------------------

(±)-**11** was prepared in a manner similar to that used for (±)-**12** in 35% yield. ^1^H NMR (CDCl~3~, 300 MHz) δ 8.28 (s, 1H), 7.90--7.75 (m, 4H), 7.60--7.50 (m, 2H), 7.23 (d, *J* = 8.5 Hz, 2H), 6.94 (d, *J* = 8.5 Hz, 2H), 6.53 (d, *J* = 7.7 Hz, 1H), 4.40--4.20 (m, 1H), 3.00--2.40 (m, 6H), 2.25--1.70 (m, 6H), 1.60--1.50 (m, 2H), 1.25--1.00 (m, 2H), 0.89 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (CDCl~3~, 75 MHz) δ 167.21, 140.12, 134.93, 132.82, 131.83, 131.72, 129.14, 128.71, 128.67, 127.95, 127.84, 127.58, 127.25, 126.96, 123.75, 71.19, 57.69, 53.27, 48.76, 44.73, 44.57, 37.51, 34.44, 24.94, 20.15, 17.02, 12.23.

*N*-(*cis*-3-(2-((((±)-*trans*)-2-(3-Chlorophenyl)cyclopropyl)(propyl)-amino)ethyl)-3-hydroxycyclobutyl)-2-naphthamide ((±)-**13**) {#sec4.8}
-----------------------------------------------------------------------------------------------------------------------------------

(±)-**13** was prepared in a manner similar to that used for (±)-**12** in 32% yield. ^1^H NMR (CD~3~OD, 300 MHz) δ 8.39 (s, 1H), 8.00--7.80 (m, 4H), 7.70--7.50 (m, 2H), 7.40--7.10 (m, 4H), 4.25--4.10 (m, 1H), 3.60--3.10 (m, 5H), 2.75--2.65 (m, 3H), 2.35--2.10 (m, 4H), 1.90--1.50 (m, 4H), 1.05 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (CD~3~OD, 75 MHz) δ 170.14, 141.61, 136.45, 136.01, 134.20, 132.86, 131.60, 130.18, 129.50, 129.04, 128.95, 128.51, 128.04, 127.45, 126.01, 125.09, 69.05, 58.49, 53.47, 46.64, 44.42, 44.27, 38.47, 34.50, 23.42, 19.02, 14.99, 11.41.

*N*-(*cis*-3-(2-(((1*S*,2*R*)-2-(4-Chlorophenyl)cyclopropyl)(propyl)-amino)ethyl)-3-hydroxycyclobutyl)-2-naphthamide ((1*S*,2*R*)-**11**) {#sec4.9}
-----------------------------------------------------------------------------------------------------------------------------------------

*N*-(*cis*-3-Hydroxy-3-(2-oxoethyl)cyclobutyl)-2-naphthamide (191 mg, 0.67 mmol), sodium triacetoxyborohydride (212 mg, 1.01 mmol), and AcOH (60 mg, 1.01 mmol) were added to a solution of (1*S*,2*R*)-**17** (140 mg, 0.67 mmol) in CH~2~Cl~2~ (20 mL), and the mixture was stirred at room temperature for 4 h. The reaction was quenched by addition of H~2~O (30 mL), and the mixture was extracted with CH~2~Cl~2~ (30 mL × 3). The organic solvent was removed under vacuum, and the residue was chromatographed (MeOH:EtOAc = 10:90) to give (1*S*,2*R*)-**11** (79 mg, 25% yield) as a colorless oil. ^1^H NMR (CDCl~3~, 300 MHz) δ 8.28 (s, 1H), 7.90--7.75 (m, 4H), 7.60--7.50 (m, 2H), 7.23 (d, *J* = 8.5 Hz, 2H), 6.94 (d, *J* = 8.5 Hz, 2H), 6.53 (d, *J* = 7.7 Hz, 1H), 4.40--4.20 (m, 1H), 3.00--2.40 (m, 6H), 2.25--1.70 (m, 6H), 1.60--1.50 (m, 2H), 1.25--1.00 (m, 2H), 0.89 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (CDCl~3~, 75 MHz) δ 167.21, 140.12, 134.93, 132.82, 131.83, 131.72, 129.14, 128.71, 128.67, 127.95, 127.84, 127.58, 127.25, 126.96, 123.75, 71.19, 57.69, 53.27, 48.76, 44.73, 44.57, 37.51, 34.44, 24.94, 20.15, 17.02, 12.23.

*N*-(*cis*-3-(2-(((1*R*,2*S*)-2-(4-Chlorophenyl)cyclopropyl)(propyl)-amino)ethyl)-3-hydroxycyclobutyl)-2-naphthamide ((1*R*,2*S*)-**11**) {#sec4.10}
-----------------------------------------------------------------------------------------------------------------------------------------

(1*R*,2*S*)-**11** was prepared in 35% yield in a manner similar to that used for (1*S*,2*R*)-**11**, except that (1*S*)-(−)-2,10-camphorsultam was used as a chiral auxiliary. ^1^H NMR (CDCl~3~, 300 MHz) δ 8.28 (s, 1H), 7.90--7.75 (m, 4H), 7.60--7.50 (m, 2H), 7.23 (d, *J* = 8.5 Hz, 2H), 6.94 (d, *J* = 8.5 Hz, 2H), 6.53 (d, *J* = 7.7 Hz, 1H), 4.40--4.20 (m, 1H), 3.00--2.40 (m, 6H), 2.25--1.70 (m, 6H), 1.60--1.50 (m, 2H), 1.25--1.00 (m, 2H), 0.89 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (CDCl~3~, 75 MHz) δ 167.21, 140.12, 134.93, 132.82, 131.83, 131.72, 129.14, 128.71, 128.67, 127.95, 127.84, 127.58, 127.25, 126.96, 123.75, 71.19, 57.69, 53.27, 48.76, 44.73, 44.57, 37.51, 34.44, 24.94, 20.15, 17.02, 12.23.

In Vitro Dopamine Receptor Binding Assays at the Rat Dopamine Receptors {#sec4.11}
-----------------------------------------------------------------------

The binding affinities of all the synthetic compounds were determined at the D~3~, D~2~, and D~1~-like receptors in membranes prepared from the brains of adult, male Sprague--Dawley rats (Pel-Freez, Rogers, AR). All compounds were dissolved in 100% EtOH at a concentration of 5 mM.

\[^3^H\]R(+)-7-OH-DPAT Binding Assay {#sec4.12}
------------------------------------

The \[^3^H\]R-(+)-7-OH-DPAT binding assay for the rat D~3~ dopamine receptors was performed as described.^[@ref23]^ A rat ventral striatum (nucleus accumbens and olfactory tubercles) was prepared in assay buffer (50 mM Tris, 1 mM EDTA; pH 7.4 at 23 °C) to yield a final concentration of 10 mg original wet weight (oww)/mL. Membranes were incubated with \[^3^H\]R-(+)-7-OH-DPAT (0.15 nM, SA = 163 Ci/mmol; GE Healthcare) and different concentrations of the test compounds (10^--10^ to 10^--4^ M). Nonspecific binding was defined by 1 μM spiperone (Sigma-Aldrich). Assay tubes were incubated at 23 °C for 90 min. The reaction was terminated by rapid vacuum filtration. Data were analyzed using SigmaPlot 10. *K*~i~ values were calculated using *K*~D~ = 0.15 nM for \[^3^H\]7-OH-DPAT^[@ref23]^ and are expressed as the mean ± SEM of 3--5 independent determinations.

\[^3^H\]Spiperone Binding Assay {#sec4.13}
-------------------------------

\[^3^H\]Spiperone binding assays for rat D~2~-like receptors were performed as described^[@ref24]^ for \[^3^H\]R-(+)-7-OH-DPAT with the following modifications. Assays were performed using membranes prepared from rat caudate-putamen, which expresses D~2~ receptors in high density but with very low levels of D~3~ receptors, and the final membrane homogenate concentration was 1.5 mg oww/mL. The assay buffer was 50 mM Tris-HCl, 5 mM KCl, 2 mM MgCl~2~, and 2 mM CaCl~2~, pH 7.4 at 23 °C; the concentration of \[^3^H\]spiperone (60--96 Ci/mmol; GE Healthcare, PerkinElmer, or American Radiolabeled Chemicals) was 0.2 nM, and the incubation time was 90 min at 23 °C. Nonspecific binding was defined in the presence of 1 μM (+)-butaclamol (Sigma-Aldrich). *K*~i~ values were calculated using the experimentally determined *K*~D~ value for \[^3^H\]spiperone of 0.4 nM.

\[^3^H\]SCH 23390 Binding Assay {#sec4.14}
-------------------------------

\[^3^H\] SCH 23390 binding assay for rat D~1~-like dopamine receptors was performed as described^[@ref33]^ for \[^3^H\]spiperone binding except the concentration of \[^3^H\]SCH 23390 (60 Ci/mmol; American Radiolabeled Chemicals) was 0.3 nM. *K*~i~ values were calculated using the *K*~D~ value for \[^3^H\]SCH 23390 of 0.3 nM.

In Vitro Dopamine Receptor Binding Assays at the Human Dopamine Receptors {#sec4.15}
-------------------------------------------------------------------------

HEK293 cells stably expressing human dopamine D~2~ and D~3~ receptors were grown in a 1:1 mixture of DMEM and Ham's F12 culture media, supplemented with 20 mM HEPES, 2 mM [l]{.smallcaps}-glutamine, 0.1 mM nonessential amino acids, 1× antibiotic/antimycotic, 10% heat-inactivated fetal bovine serum, and 200 μg/mL hygromycin (Life Technologies, Grand Island, NY) and kept in an incubator at 37 °C and 5% CO~2~. Upon reaching 80--90% confluence, cells were harvested using premixed Earle's Balanced Salt Solution (EBSS) with 5 μM EDTA (Life Technologies) and centrifuged at 3000 rpm for 10 min at 21 °C. The supernatant was removed, and the pellet was resuspended in 10 mL of hypotonic lysis buffer (5 mM MgCl~2~·6H~2~O, 5 mM Tris, pH 7.4 at 4 °C) and centrifuged at 20000 rpm for 30 min at 4 °C. The pellet was then resuspended in fresh EBSS buffer made from 8.7 g/L Earle's Balanced Salts without phenol red (US Biological, Salem, MA), 2.2 g/L sodium bicarbonate, pH to 7.4. A Bradford protein assay (Bio-Rad, Hercules, CA) was used to determine the protein concentration, and membranes were diluted to 500 μg/mL and stored in a −80 °C freezer for later use.

Immediately prior to testing, all test compounds were freshly dissolved in 30% DMSO and 70% H~2~O to a stock concentration of 100 μM. To assist the solubilization of free-base compounds, 10 μL of glacial acetic acid was added along with the DMSO. Each test compound was then diluted into 13 half-log serial dilutions using 30% DMSO vehicle; final test concentrations ranged from 10 μM to 10 pM. Previously frozen membranes were diluted in fresh EBSS to a 100 μg/mL stock for binding. Radioligand competition experiments were conducted in glass tubes containing 300 μL of fresh EBSS buffer with 0.2 mM sodium metabisulfite, 50 μL of diluted test compound, 100 μL of membranes (10 μg total protein), and 50 μL of \[^3^H\]*N*-methylspiperone (0.4 nM final concentration; PerkinElmer). Nonspecific binding was determined using 10 μM butaclamol (Sigma-Aldrich, St. Louis, MO), and total binding was determined with 30% DMSO vehicle. All compound dilutions were tested in triplicate and the reaction incubated for 1 h at room temperature. The reaction was terminated by filtration through Whatman GF/B filters, presoaked for 1 h in 0.5% polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments, Gaithersburg, MD). The filters were washed 3 times with 3 mL of ice-cold EBSS buffer and transferred to scintillation vials. Then 3 mL of CytoScint liquid scintillation cocktail (MP Biomedicals, Solon, OH) was added and vials were counted using a PerkinElmer Tri-Carb 2910 TR liquid scintillation counter (Waltham, MA). IC~50~ values for each compound were determined from dose--response curves, and *K*~i~ values were calculated using the Cheng--Prusoff equation.^[@ref34]^ These analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA). Reported *K*~i~ values were determined from least three independent experiments.

Dopamine D~3~ β-Arrestin Functional Assay {#sec4.16}
-----------------------------------------

Functional activity at the D~3~ receptor was determined using a PathHunter eXpress β-arrestin assay kit (DiscoveR~x~, Fremont, CA) for human D~3~ receptors transfected in U20S cells.^[@ref30]^ Compounds were screened for agonist and antagonist activity according to the manufacturer's instructions. Pramipexole (100 nM) was used as the reference agonist. Data were analyzed using SigmaPlot 10 and are presented as the mean ± SEM of 4--6 independent determinations. For the Schild analysis, D~3~ activity was stimulated by pramipexole in the presence of 3 concentrations of (1*R*,2*S*)-**11** and analyzed according to the methods of Kenakin.^[@ref31]^

Experimental details of chemical synthesis and chemical data. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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